期刊文献+

多奈哌齐不良反应的研究进展 被引量:1

Research Progress on Adverse Reactions of Donepezil
下载PDF
导出
摘要 多奈哌齐是第二代特异的可逆性中枢乙酰胆碱酯酶抑制剂(Acetylcholinesterase inhibitors,ACh EIs),主要用于阿尔兹海默症(Alzheimer’s disease,AD)、血管性痴呆等疾病的治疗,临床应用广泛。通过对近年来关于多奈哌齐不良反应的文献进行综述,发现多奈哌齐引起的不良反应主要包括胃肠道反应、心律失常、精神紊乱等,以期为临床合理用药提供参考。 Donepezil is one of the second-generation specific reversible central acetylcholinesterase inhibitors(ACh EIs).It iswidely applicatedin the treatment of Alzheimer’s disease(AD),vascular dementia and other diseases in clinical practice.In order to provide a scientific basis for clinical applications,this articlesummarized the adverse reactions of donepezil.By reviewing the relevant literature in recent years,it was foundthat the adverse reactions of donepezil weremainly gastrointestinal reactions,arrhythmias and mental disorders.
作者 于飞 陈佩佩 李紫璇 颜久兴 YU Fei;CHEN Pei-pei;LI Zi-xuan;YAN Jiu-xing(School of Pharmacy,Tianjin Medical University,Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics,Tianjin 300070,China)
出处 《中国药物评价》 2022年第5期422-426,共5页 Chinese Journal of Drug Evaluation
基金 天津市教委科研计划项目(项目编号:2019KJ178 项目名称:盐酸多奈哌齐与盐酸莫西沙星联合用药不良反应作用机理研究)。
关键词 多奈哌齐 阿尔兹海默症 不良反应 胃肠道反应 Donepezil Alzheimer’s disease Adverse reactions Gastrointestinal reactions
  • 相关文献

参考文献4

二级参考文献26

  • 1Elliott ES, Marken PA, Ruehter VL. Clozapine-associated extrapyramidal reaction [J]. Ann Pharmacother, 2000,34 ( 5 ) : 615-618.
  • 2Li CR, Chung YC, Park TW, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first- line antipsychotic drug[ J]. World J Biol Psychiatry, 2009,10 (4 Pt 3) :919-924.
  • 3De Lucena D, Fernandes BS, Berk M, et al. Improvement of negative and positive symptoms in treatment-refractory schizo phrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine [J]. Clin Psy- chiatry ,2009,70 ( 10 ) : 1416 -1423.
  • 4Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia [J]. Child Adolesc Psychopharmacol,2009,19 (6) :611-621.
  • 5De la Gandara J, San Molina L, Rubio G,et al. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia:the SPHERE Study[ J]. Expert Rev Neurother,2009,9 ( 10 ) : 1463-1474.
  • 6Hawley C, Turner M, Latif MA, et al. Switching stable patients with schizophrenia from depot and oral antipsychotics to longacting injectable risperidone:reasons for switching and safety [ J]. Hum Psychopharmacol,2009,25 ( 1 ) :37-46.
  • 7Hori H, Ueda N, Yoshimura R, et al. Olanzapine orally disintegrating tablets (Zyprexa Zydis )rapidly improve excitement components in the acute phase of first-episode schizophrenic patients:an open-label prospective study [ J ]. World J Biol Psychiatry,2009,10 (4 Pt 3 ) :741-745.
  • 8Kramer M, Litman R, Hough D. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study [ J ]. Int J Neuropsychopharmacol,2010, 13 : 635-647.
  • 9Bishara D, Taylor D. Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder [ J ]. Neuropsychiatr Dis Treat,2010,13(5) :635-647.
  • 10Grootens KP, Van Veelen NM, Peuskens J, et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial[ J ]. Schizophr Bull,2011,37 (2) :352-361.

共引文献29

同被引文献25

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部